Toronto Dominion Bank
VIR icon

Toronto Dominion Bank’s Vir Biotechnology VIR Stock Holding History

Toronto Dominion Bank’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 1725
2022
Q2 		$0 Hold
1
– – ﹤0.01% 1912
2022
Q1 		$0 Hold
1
– – ﹤0.01% 2016
2021
Q4 		$0 Buy
+1
New +$39 ﹤0.01% 2034

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Toronto Dominion Bank's VIR Position: Q3 2022 in Review

Toronto Dominion Bank sold out of Vir Biotechnology (VIR) in Q3 2022, closing a stake of 1 share.

Toronto Dominion Bank first reported a position in VIR in Q4 2021 and held it in 3 quarters. The position peaked at $0 in Q2 2022. 220 funds tracked by Wall St. Rank hold VIR as of Q3 2022.

  • Toronto Dominion Bank reported no remaining Vir Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Toronto Dominion Bank sold 1 Vir Biotechnology share in Q3 2022.
  • Toronto Dominion Bank first reported a position in Vir Biotechnology in Q4 2021 and held it in 3 quarters.
  • Toronto Dominion Bank's Vir Biotechnology position peaked at $0 in Q2 2022.
  • 220 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2022.

Based on Toronto Dominion Bank's 13F filing for Q3 2022, filed 9 Nov 2022.